A study of more than 300 patients finds that the risk for thromboembolic events remains high in patients with nephrotic ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

USA: An interim analysis of the Phase 3 VISIONARY study revealed that sibeprenlimab achieved a significant and clinically ...

IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that the overactivation of the lectin pathway contributes to the pathogenesis ...

The following is a summary of “Association between different proportions of crescents and the progression of IgA nephropathy ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

As part of its ongoing RAK diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the LINK between diabetes and kidney disease, shedding light on the prevention ...

Table 1. Diabetic Nephropathy Stages: Cutoff Values of Urine Albumin for Diagnosis and Main Clinical Characteristics Stages Albuminuria cutoff values (ref. 14) Clinical characteristics (ref. no.) ...

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for syste ...

As part of its ongoing RAK Diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the ...

Breakthrough status for nephropathy drug lifts Omeros The FDA has given breakthrough therapy designation to OMS721, a new treatment for the rare kidney disease immunoglobulin A (IgA) nephropathy.